SOURCE: Benda Pharmaceutical, Inc.

May 24, 2007 11:30 ET

Benda Pharmaceutical, Inc. to Host Conference Call on May 30, 2007 to Review First Quarter 2007 Financial Results

HUBEI PROVINCE, CHINA -- (MARKET WIRE) -- May 24, 2007 --Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing conventional and Traditional Chinese Medicines, as well as Genedicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, will host a conference call on Wednesday, May 30, 2007 to review first quarter 2007 earnings results. The conference call is scheduled for 9:00 am, Eastern Time. To participate in the call, please dial:

             U.S. and Canada: 1 (800) 374-0113
             International:   1 (706) 758-9607
             Conference ID:   2210888
A replay of the call will be available two hours after completion. You will be able to access it at any time through the Benda Website at www.BendaPharma.com, or by phone until June 30, 2007. To access the replay by phone, please dial:
             U.S. and Canada: 1 (800) 642-1687
             International:   1 (706) 645-9291
             Conference ID:   2210888
About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.BendaPharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces conventional and Traditional Chinese Medicines, as well as Genedicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information